- Home
- CDNS vs BMY Comparison
CDNS vs BMY Comparison
Compare CDNS & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDNS | BMY |
|---|---|---|
| Founded | 1988 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.8B | 113.5B |
| IPO Year | 1994 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CDNS | BMY |
|---|---|---|
| Price | $325.31 | $63.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $375.00 | $61.73 |
| AVG Volume (30 Days) | 2.4M | ★ 11.8M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | 5.45 | ★ 178.46 |
| EPS | 1.23 | ★ 2.93 |
| Revenue | $5,296,759,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $16.00 | N/A |
| Revenue Next Year | $12.39 | N/A |
| P/E Ratio | $263.23 | ★ $22.06 |
| Revenue Growth | ★ 14.12 | N/A |
| 52 Week Low | $262.75 | $42.52 |
| 52 Week High | $416.69 | $68.10 |
Technical Indicators
Market Signals| Indicator | CDNS | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 38.17 | 58.70 |
| Support Level | $325.81 | $56.46 |
| Resistance Level | $341.31 | $68.10 |
| Average True Range (ATR) | 11.64 | 1.79 |
| MACD | -0.15 | -0.22 |
| Stochastic Oscillator | 18.74 | 33.48 |
Price Performance
Historical ComparisonAbout CDNS Cadence Design Systems Inc.
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enables system-level analysis and verification solutions.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.